Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy: Nineteen analysts give Phreesia a consensus rating of “Moderate Buy” (12 buys, 6 holds, 1 sell) with an average 12‑month price target of about $20.82.
• Q1 results and valuation: Phreesia reported a Q1 EPS miss of $0.02 vs. $0.07 expected while revenue rose 15.9% YoY to $127.07M; the stock trades around $9.66 (1‑year range $7.77–$32.76) with a market cap of ~$587M and a P/E of ~322.
• Insider and institutional activity: Insiders sold 50,493 shares (~$462K) in the past three months under Rule 10b5‑1 plans to cover taxes, insiders own 5.5% of the company, and institutional investors hold about 92.1% of the stock.

Phreesia, Inc. (NYSE:PHR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nineteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $20.8235.

A number of research analysts have weighed in on the stock. Stephens dropped their price objective on shares of Phreesia from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 31st. Royal Bank Of Canada started coverage on shares of Phreesia in a report on Friday, January 9th. They issued a "moderate buy" rating and a $26.00 target price for the company. Mizuho lowered their target price on shares of Phreesia from $22.00 to $19.00 and set an "outperform" rating for the company in a report on Tuesday, March 24th. BMO Capital Markets lowered their target price on shares of Phreesia from $32.00 to $14.00 and set an "outperform" rating for the company in a report on Tuesday, March 31st. Finally, Citizens Jmp reiterated a "market perform" rating on shares of Phreesia in a report on Wednesday, April 1st.

Phreesia Stock Down 0.1%

Phreesia stock opened at $9.66 on Wednesday. Phreesia has a 1-year low of $7.77 and a 1-year high of $32.76. The firm has a market capitalization of $587.12 million, a price-to-earnings ratio of 322.10 and a beta of 0.89. The firm's fifty day moving average price is $10.37 and its two-hundred day moving average price is $15.24. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.41.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The business had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. During the same period last year, the business posted ($0.11) earnings per share. The firm's quarterly revenue was up 15.9% on a year-over-year basis. On average, equities research analysts predict that Phreesia will post 0.28 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Yvonne Hui sold 10,063 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $9.08, for a total transaction of $91,372.04. Following the completion of the sale, the insider owned 25,991 shares in the company, valued at approximately $235,998.28. This trade represents a 27.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Linetsky sold 8,332 shares of the firm's stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the sale, the insider owned 224,056 shares of the company's stock, valued at $1,808,131.92. This trade represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 50,493 shares of company stock worth $461,983. Company insiders own 5.50% of the company's stock.

Institutional Trading of Phreesia

A number of large investors have recently added to or reduced their stakes in PHR. Federated Hermes Inc. purchased a new stake in Phreesia during the third quarter worth about $32,000. Van ECK Associates Corp increased its holdings in Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock worth $42,000 after buying an additional 1,102 shares during the last quarter. New York State Teachers Retirement System purchased a new stake in Phreesia during the first quarter worth about $44,000. Asset Management One Co. Ltd. purchased a new stake in Phreesia during the third quarter worth about $45,000. Finally, Rockefeller Capital Management L.P. increased its holdings in Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after buying an additional 2,149 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.